NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,761.00+₹3.50 (+0.2%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.97% below the high.
Loading market information…
NSE · GLAND.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 03:39 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Gland Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 3.04% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Gland Pharma Limited’s forward annual dividend is ₹20.00 per share, paid annual. The forward yield is 0.65% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
BEHIND THE RESULTS
Gland Pharma Limited’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of ₹16.73. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Gland Pharma Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Gland Pharma Limited, established in Hyderabad, India, in 1978, is a pharmaceutical company that specializes in the creation, production, and global distribution of generic injectable medications. Its product line features key active pharmaceutical ingredients such as heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, among others. The company's extensive therapeutic portfolio encompasses anti-infectives, anesthetics, anticoagulants, antimalarials, cardiovascular drugs, gastrointestinal treatments, pain management, hormones, fertility aids, anti-cancer agents, gynecological remedies, neurological and central nervous system medications, respiratory treatments, blood-related products, ophthalmological and otological solutions, orthopedics, hematinics, and various vitamins, minerals, and nutrients. Additionally, Gland Pharma provides contract development services. The company primarily operates on a business-to-business (B2B) model, distributing its products across major markets including the United States, Europe, Canada, Australia, India, and other international territories. Gland Pharma Limited functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:44 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | May 20, 2025 | ₹11.27-9.7% vs estimate | ₹14.21B-7.49% vs estimate |
|---|
| Q3 2025 | Feb 3, 2025 | ₹12.40-4.62% vs estimate | ₹13.84B-9.82% vs estimate |
|---|
| Q2 2025 | Nov 4, 2024 | ₹9.93-7.71% vs estimate | ₹14.06B-1.4% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,761.00+₹3.50 (+0.2%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.97% below the high.
₹2,244.00+₹62.10 (+2.85%)
Laurus Labs Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
₹1,345.00+₹9.60 (+0.72%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.94% below the high.
₹1,358.00-₹7.60 (-0.56%)
Cipla Limited’s quoted price sits in the lower half of its reported 52-week range, 14.77% below the high.
₹2,469.30-₹20.70 (-0.83%)
Mankind Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 6.54% below the high.
₹1,989.90+₹17.20 (+0.87%)
Lupin Limited’s quoted price sits in the lower half of its reported 52-week range, 21.33% below the high.
₹5,079.00+₹9.00 (+0.18%)
Alkem Laboratories Limited’s quoted price sits in the lower half of its reported 52-week range, 14.4% below the high.
₹1,926.20-₹4.30 (-0.22%)
Ipca Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 5.49% below the high.
